Determination of HE4-mediated roles in tumor immune system modulation in epithelial ovarian cancer (EOC)

Urh, Anze; Romano, N; Han, Alex; Ribeiro, Jennifer; Yano, Naohiro; Kim, K.; Singh, Rakesh K.; Moore, Richard G.

doi:10.1016/j.ygyno.2015.01.435

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surgery and chemotherapy are the important means of clinical treatment for ovarian cancer at present [4]. Previous studies have confirmed that the immune system function in patients with ovarian cancer is significantly inhibited at the onset, and immune activity factors and cell function are significantly reduced, which further aggravates the growth and migration of tumor cells [5–7].…”

Section: Introductionmentioning

confidence: 99%

Effect of Dexmedetomidine-Mediated Insulin-Like Growth Factor 2 (IGF2) Signal Pathway on Immune Function and Invasion and Migration of Cancer Cells in Rats with Ovarian Cancer

et al. 2019

View full text Add to dashboard Cite

Background The aim of this study was to explore the effect of dexmedetomidine (DEX)-mediated insulin-like growth factor 2 (IGF2) signal pathway on immune function and cancer cell invasion and migration in rats with ovarian cancer. Material/Methods Forty rats with ovarian cancer were divided into 4 groups: model group, and low dose (0.2 μg/kg/hour DEX), medium dose (1.0 μg/kg/hour DEX), and high dose (5.0 μg/kg/hour DEX) DEX groups. In addition, 10 Fischer344 rats were selected as a normal group. Human NUTU-19 poorly differentiated epithelial ovarian cancer cell line cells were divided into 4 groups: a blank group and low dose, medium dose, and high dose DEX NUTU-19 groups. Results Compared with the normal group, in the other groups the serum interleukin (IL)-2 and interferon gamma (INF-γ) levels, CD4 + and CD8 + percentages, CD4 + /CD8 + ratio, and transformation rate of splenic lymphocytes were decreased, and the serum tumor necrosis factor alpha (TNF-α) level, IGF2, insulin-like growth factor 1 receptor (IGF1R), insulin receptor substrate 1 (IRS1) mRNA, and protein expressions in ovarian tissue were increased (all P <0.05). Results in the DEX groups compared with model group were the opposite of those in the other groups compared with normal group (all P <0.05). Compared with the blank group, in the other groups the proliferation, invasion, and migration of ovarian cancer cells were reduced significantly (all P <0.05). Compared with the low dose DEX NUTU-19 group, in the high dose DEX NUTU-19 group the invasion and migration of ovarian cancer cells weakened significantly (both P <0.05). Conclusions A certain dose of DEX can effectively inhibit IGF2 signal pathway activation to improve the immune function of rats with ovarian cancer, inhibiting the invasion and migration of ovarian cancer cells.

show abstract

Section: Introductionmentioning

confidence: 99%